News

Data from two studies continue to show the long-term efficacy and safety of fixed-duration venetoclax combination regimens across different lines of therapy in CLL Six-year median follow-up from ...
AbbVie remains a Buy despite venetoclax's MDS trial failure, as this setback has minimal impact on current revenue and growth outlook. SKYRIZI and RINVOQ are successfully replacing HUMIRA's lost ...
By Denny Jacob AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.
AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of venetoclax remain unchanged.
AbbVie, in collaboration with Roche-Genentech, is conducting a Phase 3 clinical study titled ‘Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients With ...
AbbVie (ABBV) announced the global Phase 3 Vevrona trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet ...
NORTH CHICAGO - AbbVie (NYSE: ABBV), a prominent player in the biotechnology industry with annual revenue of $57.37 billion, announced today that its Phase 3 VERONA trial evaluating venetoclax in ...
By Denny Jacob AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.
NORTH CHICAGO, Ill., June 9, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new findings demonstrating sustained long-term safety and efficacy of VENCLYXTO®/ VENCLEXTA® (venetoclax ...
AbbVie indicated that detailed results from the VERONA trial will be presented at a future medical congress or in a scientific publication. Patients who received the venetoclax-azacitidine combination ...
AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.